Lilly Pulls EU Approval Application For Olumiant In COVID-19

 
• By Ian Schofield

The European Medicines Agency says it does not have enough data to justify the approval of Olumiant for hospitalized COVID-19 patients. The marketing authorization application for another product, Reata’s Imbarkyd for chronic kidney disease, has also been withdrawn.  

Microscopic view of Coronavirus, a pathogen that attacks the respiratory tract. Analysis and test, experimentation. Sars. 3d render
The EMA says it cannot approve Olumiant for COVID-19 at present • Source: Shutterstock

More from Europe

More from Geography